The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial

NCT ID: NCT03333278

Last Updated: 2019-10-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 216 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-05-02
• Study Completion Date: 2019-10-06

Brief Summary

Sepsis has been characterised as a dysregulated host response to infection. Adjunctive therapies targeting the inflammatory cascade are being increasingly explored, although to date, have failed to demonstrate consistent benefit, and sepsis continues to manifest poor outcomes. Hospital mortality in patients with septic shock remains as high as 22% in Australia and New Zealand. From a global perspective, 31 million sepsis and 19 million severe sepsis cases are expected to be treated in hospitals all over the world per year.

To date, experimental data have reported that both high dose intravenous vitamin C and corticosteroids attenuate the acceleration of the inflammatory cascade and possibly reduce the endothelial injury characteristic of sepsis, enhance the release of endogenous catecholamines and improve vasopressor responsiveness.

Therefore, the investigators plan to conduct a feasibility pilot prospective, multi-centre, randomised, open-label, trial in ICU patients with septic shock to test whether the intravenous administration of high dose Vitamin C (6g/d), Thiamine (400mg/d) and Hydrocortisone (200mg/d) leads to a more rapid resolution shock and vasopressor dependence.

Detailed Description

The investigators plan to conduct a feasibility pilot prospective, multi-centre, randomised, open-label, trial in ICU patients with septic shock to test whether the intravenous administration of high dose Vitamin C (6g/d), Thiamine (400mg/d) and Hydrocortisone (200mg/d) for a maximum of ten days leads to a more rapid resolution shock and vasopressor dependence.

Hypothesis:

Treatment with a combination of intravenous Vitamin C, Thiamine and Hydrocortisone reduces duration of vasopressor (measured by hours alive and vasopressor free) use censored at 7 days compared to standard care with Hydrocortisone alone.

This is a prospective, feasibility, pilot, multi-centre, randomised, open-label controlled trial. This study will be performed in seven Victorian ICUs in Australia. Patients admitted to an ICU of the participating hospitals with the primary diagnosis of septic shock will be screened for inclusion into this study.

Rationale:

Experimental data have demonstrated that both corticosteroids and intravenous vitamin C attenuate the release of pro-inflammatory mediators, reduce the endothelial injury characteristic of sepsis (thereby reducing endothelial permeability and improving microcirculatory flow), augment the release of endogenous catecholamines and enhance vasopressor responsiveness. In animal models, these effects have resulted in reduced organ injury and increased survival. However, their effect in critically ill humans is unknown.

Previous research suggests that vitamin C and glucocorticoids may act synergistically and improve vasopressor responsiveness in patients with sepsis and septic shock.

Randomisation:

ICU patients will be enrolled as soon as possible but no later than 24 hours after fulfilling the criteria for septic shock. Patients will be allocated in a 1:1 ratio to either the treatment group, receiving intravenous Vitamin C (1.5g every 6 hours), Thiamine (200mg every 12 hours) and Hydrocortisone (50mg every 6 hours), or to the control group, receiving Hydrocortisone (50mg every 6 hours) alone.

Treatment allocation will occur using a computerized system and concealed allocation. The clinical staff involved in patient care will administer the additional drugs to those allocated to the treatment arm of the trial as soon as possible after the identification of septic shock and randomization.

Patients readmitted to ICU during the same hospital stay will not receive any further doses of study drugs.

Study Treatment will continue until:

• Septic shock resolves
• The patient leaves the ICU
• Contraindications to Vitamin C, Thiamine or Hydrocortisone therapy arise
• Death occurs
• A maximum of 10 days of treatment has been administered
• Serious adverse events suspected to be secondary to the intervention therapy develop.

Study Drugs

This study will be an open label study:

Intervention group:

• 1500mg Vitamin C is will be diluted in 100ml of Normal Saline (0.9% NaCl) and infused over 1 hour. The dosing schedule is 1500mg every 6 hours for the duration of study treatment.
• 200mg Thiamine will be diluted in 100ml of Normal Saline (0.9% NaCl) and infused over 1 hour. The dosing schedule is 200mg every 12 hours. Patients in the control group of the study can receive thiamine if clinically indicated at the discretion of the attending ICU staff specialist.

In both groups (treatment and control), patients will be treated with hydrocortisone 50mg IV q 6 hourly for the duration of study treatment. After shock resolution and/or a maximum fo 7 days Hydrocortisone will be tapered off or stopped.

Statistical analysis:

Originally, the investigators assumed a mean (SD) duration of vasopressor dependency of 50 (28) hours and estimated a required sample size of 120 patients (60 per group) to identify a clinically relevant decrease of vasopressor dependency and an increase in days alive and vasopressor free at 7 days of 25% (20 hours) (i.e. increase from 41 to 55 hours of days alive and vasopressor free at day 7) with a power of 90% at an alpha level of 0.05.

The investigators have recalculated the sample size based on the pooled standard deviation of hours alive and vasopressor free of the first 59 participants. The pooled standard deviation of hours alive and vasopressor free at 7 days for the 59 patients is 51.6 hours.

To have a 90% power (2 sided p-value of 0.05) to detect a 25-hour difference based on a standard deviation of 51.6, the trial will require 180 patients (90 per group). Allowing for a 20% inflation for non-normality and dropout/withdrawal, the required total sample size is 216 (108 per group). The robustness of the sample size estimate will be further assessed after recruitment of 108 patients (50% of the sample size).

Consent: The major ethical issues associated with this study relate involve the recruitment of participants who are dependent on medical care and in need of immediate intervention for the management of life-threatening haemodynamic instability.

1. Informed consent from participant or substitute/medical treatment decision maker: Where possible, and as authorised by law, which varies between jurisdictions, consent will be obtained from the participant himself or from the participant's legal surrogate if the patient lacks decision-making capacity.

2. Consent to continue: Where it is not possible or practicable for the patient or the legal surrogate to consider the study and give consent immediately, the patient may be enrolled with a waiver of consent (or medical research procedures in an emergency in Victoria) and consent obtained from the participant's legal surrogate as soon as possible, provided the procedure is in accord with the requirements of the site's Human Research Ethics Committee (HREC) and applicable legislation. When appropriate, the participant's legal surrogate, and, in turn, the participant, will be informed of the study and will be able to withdraw consent for ongoing participation at any time.

3. Verbal/Telephone consent: In cases where the participant's legal surrogate cannot attend the hospital to sign the consent form within the time constraints of the study, consent for patient participation in the study may be obtained over the telephone in accordance with local HREC guidelines. The telephone conversation must be documented in the patient's medical record. As soon as the participant's legal surrogate is able to attend the hospital, they will be asked to sign a consent form and note that telephone consent was already provided.

Once subjects are recovered and are able to consider the information sheet, they will be offered the opportunity to withdraw from study follow-up. If a participant dies due to the nature of their critical illness before consent was able to be obtained from the person responsible/medical treatment decision maker, then consent will not be sought and data collected will be used. This is in line with the process followed by other similar intensive care studies conducted previously and approved by the relevant HRECs all where consent to continue has been utilised.

Conditions

Shock, Septic; Critically Ill; Vasoplegic Syndrome; Sepsis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vitamins

intravenous: Ascorbic acid (Vitamin C: 1.5g every 6 hours) Thiamine (Vitamin B1: 200mg every 12 hours) Hydrocortisone (50mg every 6 hours)

Group Type: ACTIVE_COMPARATOR

Vitamin C

Intervention Type: DRUG

Ascorbic acid 1.5g every 6 hours i.v. while in ICU, until shock resolution for a maximum of ten days

Thiamine

Intervention Type: DRUG

Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days

Hydrocortisone,

Intervention Type: DRUG

Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.

Control

Hydrocortisone (50mg every 6 hours)

Group Type: OTHER

Hydrocortisone,

Intervention Type: DRUG

Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.

Interventions

Vitamin C

Ascorbic acid 1.5g every 6 hours i.v. while in ICU, until shock resolution for a maximum of ten days

Intervention Type: DRUG

Thiamine

Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days

Intervention Type: DRUG

Hydrocortisone,

Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.

Intervention Type: DRUG

Other Intervention Names

Ascorbic acid; Vitamin B1; Solu Cortef

Eligibility Criteria

Inclusion Criteria

Patient in the intensive care unit (ICU) with septic shock:

• Blood lactate >2 mmol/L, despite adequate fluid resuscitation AND
• need for continuous vasopressor therapy to keep mean arterial pressure (MAP) >65 mmHg for >2 hours

Exclusion Criteria

1. Age < 18 years

2. Pregnancy

3. DNR (do not resuscitate)/DNI (do not intubate) orders

4. Death is deemed to be imminent or inevitable during this admission, and either the attending physician, patient or substitute decision-maker is not committed to active treatment

5. Patients with known HIV infection

6. Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency

7. Patients transferred from another ICU or hospital with a diagnosis of a septic shock for > 24 hours

8. Patients with a diagnosis of a septic shock for > 24 hours

9. Patients with known or suspected

• a. history of oxalate nephropathy or hyperoxaluria
• b. short bowel syndrome or severe fat-malabsorption
• c. acute beri-beri disease
• d. acute Wernicke's encephalopathy
• e. malaria
• f. scurvy
• g. Addison's disease
• h. Cushing's disease

10. Clinician expects to prescribe systemic glucocorticoids for an indication other than septic shock (not including nebulised or inhaled corticosteroid)

11. Patient is receiving treatment for systemic fungal infection or has documented Strongyloides infection at the time of randomisation

12. Patient with known chronic iron overload due to iron storage and other diseases

13. Patient previously enrolled in this study

14. Clinician expects to prescribe high dose vitamin C for another indication

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Austin Hospital, Melbourne Australia

OTHER

Sponsor Role: collaborator

Melbourne Health

OTHER

Sponsor Role: collaborator

Barwon Health

OTHER_GOV

Sponsor Role: collaborator

Monash Health

OTHER

Sponsor Role: collaborator

The Alfred

OTHER

Sponsor Role: collaborator

Wellington Hospital

OTHER_GOV

Sponsor Role: collaborator

Western Health, Australia

OTHER_GOV

Sponsor Role: collaborator

Australian and New Zealand Intensive Care Research Centre

OTHER

Sponsor Role: lead

Responsible Party

anzicrc

Professor Rinaldo Bellomo

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Rinaldo Bellomo, Professor

Role: PRINCIPAL_INVESTIGATOR

Austin Hospital, Melbourne Australia

Nora Luethi, MD

Role: PRINCIPAL_INVESTIGATOR

ANZIC-RC

Tomoko Fujii, MD

Role: PRINCIPAL_INVESTIGATOR

ANZIC-RC

Locations

Monash Health (Monash Medical Centre and Dandenong Hospital)

Clayton, Victoria, Australia

Geelong University Hospital

Geelong, Victoria, Australia

Austin Health

Heidelberg, Victoria, Australia

Alfred Hospital

Melbourne, Victoria, Australia

Western Health (Footscray & Sunshine Hospital)

Melbourne, Victoria, Australia

Royal Melbourne Hospital

Melbourne, Victoria, Australia

Cancer Institute of the State of São Paulo

São Paulo, , Brazil

Wellington Hospital

Wellington, , New Zealand

Countries

Australia; Brazil; New Zealand

References

Fujii T, Luethi N, Young PJ, Frei DR, Eastwood GM, French CJ, Deane AM, Shehabi Y, Hajjar LA, Oliveira G, Udy AA, Orford N, Edney SJ, Hunt AL, Judd HL, Bitker L, Cioccari L, Naorungroj T, Yanase F, Bates S, McGain F, Hudson EP, Al-Bassam W, Dwivedi DB, Peppin C, McCracken P, Orosz J, Bailey M, Bellomo R; VITAMINS Trial Investigators. Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial. JAMA. 2020 Feb 4;323(5):423-431. doi: 10.1001/jama.2019.22176.

Reference Type: DERIVED

PMID: 31950979 (View on PubMed)

Fujii T, Udy AA, Deane AM, Luethi N, Bailey M, Eastwood GM, Frei D, French C, Orford N, Shehabi Y, Young PJ, Bellomo R; VITAMINS trial investigators. Vitamin C, Hydrocortisone and Thiamine in Patients with Septic Shock (VITAMINS) trial: study protocol and statistical analysis plan. Crit Care Resusc. 2019 Jun;21(2):119-125.

Reference Type: DERIVED

PMID: 31142242 (View on PubMed)

Other Identifiers

HREC17Austin238

Identifier Type: -

Identifier Source: org_study_id